-
公开(公告)号：US10406161B2
公开(公告)日：2019-09-10
申请号：US16144614
申请日：2018-09-27
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
2.发明申请公开(公告)号：US20190328763A1
公开(公告)日：2019-10-31
申请号：US16342871
申请日：2017-10-13
发明人： Guang CHENG , Wenzhong CHEN , Lili QIN
IPC分类号： A61K31/7088 , A61K9/51 , A61K47/24 , A61K47/26 , A61K47/10 , C12N15/113
摘要： A lipid nanoparticle for antisense oligonucleotides inhibiting bcl-2 and belonging to the technical field of biology. The lipid nanoparticle for antisense oligonucleotides inhibiting bcl-2 is prepared by coating an antisense oligonucleotide with a membrane material, and the nucleic acid sequence is 5′-TCT CCC AGC GTG CGC CAT-3′ (SEQ ID NO: 1), or 5′ UCU CCC AGC GTG CGC CAU 3′ (SEQ ID NO: 2). And a method for preparing the same is provided. The nanoparticles have a fairly good inhibitory effect on the growth of tumor cells and specific target genes, and particularly have a fairly good inhibitory effect on KB cervical cancer cells.
-
公开(公告)号：US11110094B2
公开(公告)日：2021-09-07
申请号：US16525502
申请日：2019-07-29
发明人： Kaoxiang Sun , Rongcai Liang , Oilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
公开(公告)号：US20170056407A1
公开(公告)日：2017-03-02
申请号：US15347365
申请日：2016-11-09
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
IPC分类号： A61K31/519 , A61K9/00 , A61K9/16
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/14 , A61K9/16 , A61K9/1647 , A61K9/19 , A61K9/4858 , A61K9/5031 , A61K9/5089 , A61K47/34
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
摘要翻译： 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐，以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物，其中第一未封端丙交酯 - 乙交酯共聚物是具有高的共聚物 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产，其体内释放行为在长期储存后不会改变。
-
公开(公告)号：US20200237678A1
公开(公告)日：2020-07-30
申请号：US16342804
申请日：2017-10-13
发明人： Guang CHENG , Wenzhong CHEN , Lili QIN
IPC分类号： A61K9/51 , A61K31/713
摘要： The present invention discloses a lipid nanoparticle membrane composition, and the membrane composition comprises a cationic lipid, a neutral phospholipid, cholesterol, Tween, and a polyethylene glycol derivative, with a molar ratio of (25-35):(40-50):(15-25):(1-5):(1-5) in the membrane composition. Also disclosed is a method for preparing a lipid nanoparticle from the lipid nanoparticle membrane composition. The present invention provides a lipid nanoparticle membrane composition that is capable of increasing the stability of the nanoparticle itself, thereby promoting the release of a medicament in tumor tissue and reducing the probability of being degraded.
-
公开(公告)号：US10098882B2
公开(公告)日：2018-10-16
申请号：US15347365
申请日：2016-11-09
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
公开(公告)号：US20190022098A1
公开(公告)日：2019-01-24
申请号：US16144614
申请日：2018-09-27
发明人： Kaoxiang Sun , Rongcai Liang , Qilin Wang , Wenyan Wang , Wanhui Liu , Youxin Li
IPC分类号： A61K31/519 , A61K9/19 , A61K9/50 , A61K9/00
CPC分类号： A61K31/519 , A61K9/0019 , A61K9/14 , A61K9/16 , A61K9/1647 , A61K9/19 , A61K9/4858 , A61K9/5031 , A61K9/5089 , A61K47/34
摘要： A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.012 秒)
